A. Lotfi, Siamak Mashhady Rafie, S. Hesaraki, K. Amini
{"title":"Protective Effects of Coadministration of the Vitamin E and Omega-3 on Doxorubicin-Induced Hepatotoxicity in Mice","authors":"A. Lotfi, Siamak Mashhady Rafie, S. Hesaraki, K. Amini","doi":"10.5812/ijcm-121766","DOIUrl":null,"url":null,"abstract":"Background: Doxorubicin is a favorite drug for feasting many malignancies. All organs' hepatic toxic effects are destructive and lead to use with caution. Then, it is necessary to increase antioxidants accompanied with doxorubicin to reduce its toxicity. Vitamin E is an antioxidant with harmful consequences. Omega-3 is an antioxidant similarly. The healing capacity of Vitamin E- Omega-3 was investigated together against doxorubicin. Methods: Thirty balb/c mice have divided a weight of 25 g into five equal groups of six mice each. The groups were classified as Control: normal saline; DOX: Doxorubicin; Vitamin E: Vitamin E + DOX; Omega-3; Omega-3 + DOX; Both Vitamin E- Omega-3 + DOX. The histopathology was set to describe vacuolar degeneration, inflammation, and necrosis. Immunohistochemistry was performed to estimate the expression of tumor necrosis factor (TNFα), demonstrating the inflammation. Results: DOX-induced hepatic injury and increased TNF-α expression were seen more than alone when co-administered with vitamin E and omega-3. A significant decrease was shown in the ALT, AST, GGT, and ALP levels compared to the control. The Glutathione peroxidase and Catalase enzyme activities were higher in the co-administered Vitamin E- Omega-3 group than that received Vit E or Omega-3. Conclusions: Co-administration of Vitamin E and Omega-3 have a more repair capacity with controlling effects on Doxorubicin-induced liver toxicity.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"17 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-121766","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Doxorubicin is a favorite drug for feasting many malignancies. All organs' hepatic toxic effects are destructive and lead to use with caution. Then, it is necessary to increase antioxidants accompanied with doxorubicin to reduce its toxicity. Vitamin E is an antioxidant with harmful consequences. Omega-3 is an antioxidant similarly. The healing capacity of Vitamin E- Omega-3 was investigated together against doxorubicin. Methods: Thirty balb/c mice have divided a weight of 25 g into five equal groups of six mice each. The groups were classified as Control: normal saline; DOX: Doxorubicin; Vitamin E: Vitamin E + DOX; Omega-3; Omega-3 + DOX; Both Vitamin E- Omega-3 + DOX. The histopathology was set to describe vacuolar degeneration, inflammation, and necrosis. Immunohistochemistry was performed to estimate the expression of tumor necrosis factor (TNFα), demonstrating the inflammation. Results: DOX-induced hepatic injury and increased TNF-α expression were seen more than alone when co-administered with vitamin E and omega-3. A significant decrease was shown in the ALT, AST, GGT, and ALP levels compared to the control. The Glutathione peroxidase and Catalase enzyme activities were higher in the co-administered Vitamin E- Omega-3 group than that received Vit E or Omega-3. Conclusions: Co-administration of Vitamin E and Omega-3 have a more repair capacity with controlling effects on Doxorubicin-induced liver toxicity.
期刊介绍:
International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.